Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis

References

• PercivalMELaiCEsteyEHouriganCSBone marrow evaluation for diagnosis and monitoring of acute myeloid leukemiaBlood Rev201731418519228190619
   PubMed Web of Science ®Google Scholar
• YuMGZhengHYAcute myeloid leukemia: advancements in diagnosis and treatmentChin Med J (Engl)2017130221121828091414
   PubMed Web of Science ®Google Scholar
• SmithCCWangQChinCSValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature2012485739726026322504184
   PubMed Web of Science ®Google Scholar
• RebechiMTPratzKWGenomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progressionLeuk Lymphoma2017589111
   PubMed Web of Science ®Google Scholar
• EsteyEHAcute myeloid leukemia: 2013 update on risk-stratification and managementAm J Hematol201388431832723526416
   PubMed Web of Science ®Google Scholar
• PortMBottcherMTholFPrognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysisAnn Hematol20149381279128624801015
   PubMed Web of Science ®Google Scholar
• Azari-YamATavakkoly-BazzazJSemnaniYFLT3 gene mutation profile and prognosis in adult acute myeloid leukemiaClin Lab201662102011201728164537
   PubMed Web of Science ®Google Scholar
• HassaneinMAlmahayniMHAhmedSOGaballaSElFRFLT3 inhibitors for treating acute myeloid leukemiaClin Lymphoma Myeloma Leuk2016161054354927450971
   PubMed Web of Science ®Google Scholar
• HuSNiuHMinkinPComparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemiaMol Cancer Ther2008751110112018483300
   PubMed Web of Science ®Google Scholar
• HospitalMAGreenASMacielTTFLT3 inhibitors: clinical potential in acute myeloid leukemiaOnco Targets Ther20171060761528223820
   PubMed Web of Science ®Google Scholar
• PratzKWChoELevisMJA pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia20102481437144420535150
   PubMed Web of Science ®Google Scholar
• AlvaradoYKantarjianHMLuthraRTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutationsCancer2014120142142214924737502
   PubMed Web of Science ®Google Scholar
• CooperTMCassarJEckrothEA phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) studyClin Cancer Res201622164014402226920889
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHForanJMPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJ Clin Oncol201331293681368724002496
   PubMed Web of Science ®Google Scholar
• CrumpMHedleyDKamel-ReidSA randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyLeuk Lymphoma201051225226020109071
   PubMed Web of Science ®Google Scholar
• FiedlerWKayserSKebenkoMA phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsBr J Haematol2015169569470025818407
   PubMed Web of Science ®Google Scholar
• FiedlerWServeHDohnerHA phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood2005105398699315459012
   PubMed Web of Science ®Google Scholar
• FischerTStoneRMDeangeloDJPhase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3J Clin Oncol201028284339434520733134
   PubMed Web of Science ®Google Scholar
• InabaHRubnitzJECoustan-SmithEPhase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemiaJ Clin Oncol201129243293330021768474
   PubMed Web of Science ®Google Scholar
• KnapperSBurnettAKLittlewoodTA phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood2006108103262327016857985
   PubMed Web of Science ®Google Scholar
• MacdonaldDAAssoulineSEBrandweinJA phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND186Leuk Lymphoma201354476076623061485
   PubMed Web of Science ®Google Scholar
• RamsinghGWesterveltPMcBrideAPhase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AMLInt J Hematol201499327227824488798
   PubMed Web of Science ®Google Scholar
• RavandiFAranaYCCortesJEFinal report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaLeukemia20142871543154524487412
   PubMed Web of Science ®Google Scholar
• RavandiFCortesJEJonesDPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaJ Clin Oncol201028111856186220212254
   PubMed Web of Science ®Google Scholar
• RölligCBrandtsCShaidSSurvey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemiaLeuk Lymphoma20125361062106722054287
   PubMed Web of Science ®Google Scholar
• StoneRMFischerTPaquetteRPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemiaLeukemia20122692061206822627678
   PubMed Web of Science ®Google Scholar
• ZhangWKonoplevaMShiYXMutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaJ Natl Cancer Inst2008100318419818230792
   PubMed Web of Science ®Google Scholar
• WalkerARWangHWalshKMidostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaLeuk Lymphoma20165792100210826784138
   PubMed Web of Science ®Google Scholar
• LevisMJPerlAEDombretHFinal results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantationBlood201212021673
   Google Scholar
• CortesJEPerlAEDombretHFinal results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemiaBlood20121202148
   Web of Science ®Google Scholar
• IyerSPJethavaYKaranesCEckardtJRCollinsRSafety study of salvage chemotherapy high-dose ara-C/mitoxantrone (HAM) and type I FLT3-TKI crenolanib in first relapsed/primary refractory AMLBlood20161282239833983
   Web of Science ®Google Scholar
• FathiATChenYBThe role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemiaEur J Haematol201798433033628000291
   PubMed Web of Science ®Google Scholar
• ServeHKrugUWagnerRSorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialJ Clin Oncol201331253110311823897964
   PubMed Web of Science ®Google Scholar
• KnapperSRussellNGilkesAA randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLBlood201712991143115427872058
   PubMed Web of Science ®Google Scholar
• LevisMRavandiFWangESResults from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood2011117123294330121270442
   PubMed Web of Science ®Google Scholar
• RölligCServeHHuttmannA; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialLancet Oncol201516161691169926549589
   PubMed Web of Science ®Google Scholar
• StoneRMMandrekarSSanfordBLThe multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [alliance])Blood201512623626138538
   PubMed Web of Science ®Google Scholar
• CreutzigUKaspersGJRevised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemiaJ Clin Oncol200422163432343315310791
   PubMed Web of Science ®Google Scholar
• StoneRMMandrekarSJSanfordBLMidostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutationN Engl J Med2017377545446428644114
   PubMed Web of Science ®Google Scholar
• SmithCCShahNPThe role of kinase inhibitors in the treatment of patients with acute myeloid leukemiaAm Soc Clin Oncol Educ Book20132013313318
   Google Scholar
• RölligCBornhauserMThiedeCLong-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting systemJ Clin Oncol201129202758276521632498
   PubMed Web of Science ®Google Scholar
• DohnerHEsteyEGrimwadeDDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood2017129442444727895058
   PubMed Web of Science ®Google Scholar
• Best-AguileraCRodrigoGOElizabethGAMonserratRRTreatment of acute myeloid leukemia with the FLT3 gene mutationCurr Oncol Rep20171932128283965
   PubMed Web of Science ®Google Scholar
• WanderSALevisMJFathiATThe evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondTher Adv Hematol201453657724883179
   PubMedGoogle Scholar
• StoneRMDeAngeloDJKlimekVPatients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood20051051546015345597
   PubMed Web of Science ®Google Scholar
• DöhnerHPerlARousselotPEfficacy and safety of quizartinib (AC220) in patients age ≥60 years with FLT3-ITD-positive relapsed/refractory acute myeloid leukemia (AML)Haematologica201398233
   Web of Science ®Google Scholar
• LevisMJMartinelliGPerlAEThe benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AMLJ Clin Oncol20143215_suppl7093
   Web of Science ®Google Scholar
• CortesJEKantarjianHMKadiaTMCrenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AMLJ Clin Oncol20163415_suppl7008
   Web of Science ®Google Scholar
• RandhawaJKKantarjianHMBorthakurGResults of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutationsBlood201412421389
   Web of Science ®Google Scholar
• OhanianMKantarjianHMBorthakurGEfficacy of a type I FLT3 inhibitor, crenolanib, with idarubicin and high-dose ara-C in multiply relapsed/refractory FLT3+ AMLBlood201612822274427932331
   PubMed Web of Science ®Google Scholar
• LevisMCortesJPerlAHigh response rate and bridging to hematopoietic stem cell transplantation with quizartinib (AC220) in patients with FLT3-ITD-positive relapsed/refractory acute myeloid leukemia (AML)Haematologica20139817
   Google Scholar
• FaderlSWetzlerMRizzieriDClofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trialJ Clin Oncol201230202492249922585697
   PubMed Web of Science ®Google Scholar
• RamosNRMoCCKarpJEHouriganCSCurrent approaches in the treatment of relapsed and refractory acute myeloid leukemiaJ Clin Med20154466569525932335
   PubMed Web of Science ®Google Scholar
• SatoTYangXKnapperSFLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood2011117123286329321263155
   PubMed Web of Science ®Google Scholar
• PerlAEDohnerHRousselotPHEfficacy and safety of quizartinib (AC220) in patients age 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML)J Clin Oncol20133115_suppl7023
   Google Scholar